CareBeam

The company was founded as ScribeAI and the models remain the product across every capability it has added: note generation, chart auditing, coding recommendation and the order drafting now in development. There is no services layer or platform business underneath.

Reach across documentation, auditing and coding with no published limits, and expanding further. The platform generates notes in real time, audits charts automatically, and surfaces E/M level recommendations and ICD-10 mappings, with AI assisted order drafting described as in development. No confidence threshold, accuracy rate, review gate, abstention behaviour or escalation path was located for any of it. Automated chart auditing is worth singling out: a system that reviews documentation and recommends a different billing level is performing a judgement that would normally involve a coder or compliance reviewer, and no description of what a human does with that recommendation was found.

No accuracy figure, model card, named models or evaluation methodology located. The capability set is described clearly enough, specialty aware note generation, automated chart audit, E/M level recommendation and ICD-10 mapping, but nothing is measured. For a product whose central claim is coding accuracy, the absence of any published accuracy result for the coding recommendations is the specific gap.

One named physician testimonial from a nephrologist and ACO medical director, describing reduced chart time and better reflection of care delivered. No study, controlled evaluation, accuracy benchmark, third party rating, deployment count or named institutional customer was located.

Not assessed. No statement on audio or transcript retention, de identification or training use was located in this pass.

Not assessed. No product specific business associate agreement posture was located in this pass.

Not assessed. No named or dated attestation and no trust centre located in this pass.

Not a regulated medical device and none claimed. Flag rather than grade: the platform provides on demand access to clinical guidance alongside documentation, and the relevant regulatory exposure for the rest of it is payment integrity rather than device oversight, since automated E/M recommendation sits inside coding compliance territory.

Graded on the company's own stated strategy, which is unusually explicit. CareBeam describes documentation as the entry point and says the real problems were downstream: inaccurate coding, MISSED REVENUE, and documentation that did not reflect the ACTUAL ACUITY of care delivered. Acuity capture is the mechanism at the centre of coding intensity, so this sits on the gradient this index tracks from MarianaAI and Steer Health through Sayvant, Solventum and RevMaxx. Two things place it mid gradient rather than at the aggressive end. The framing is corrective rather than maximising, and the word actual is doing real work: the claim is that documentation should match care delivered, which is also the legitimate argument against under documentation. And no revenue lift percentage is marketed and no contingent pricing was located. Even so, a system that audits a chart and recommends a higher E/M level is making a judgement a buyer's compliance function should be auditing independently. No fairness statement, subgroup analysis or accent disclosure was located.

Positioned as EHR native, with the vendor stating the platform works across documentation and revenue cycle without requiring providers to learn new tools or change existing workflows, and that output is delivered inside the record systems they already use. Held at B because no named integrations, integration architecture, certification programme membership or write back mechanism was documented or verified in this pass, so native is asserted rather than demonstrated.

Not assessed. No hosting region, residency option or sub processor detail was located.

No published rate card, tier structure or pricing model. Access is by demo request only. Given the platform spans documentation, auditing and coding support, a buyer cannot currently tell whether those are licensed together or separately.

Notes are described as specialty aware and the product is sold to independent practices, multi specialty groups and value based care organisations, with nephrology evidenced through a named user. Beyond that nothing is enumerated: no specialty count, specialty tuning detail, note format list, care setting range or language coverage was located, so breadth cannot be compared against vendors in this category that publish it.